Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Late relapse in osteosarcoma.

Stefano Ferrari1, Antonio Briccoli, Mario Mercuri

  • 1Chemotherapy of the Department of Musculoskeletal Oncology at Istituti Ortopedici Rizzoli, Bologna, Italy. stefano.ferrari@ior.it

Journal of Pediatric Hematology/Oncology
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.

Scientific reports·2026
Same author

Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group.

Critical reviews in oncology/hematology·2025
Same author

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Primary leiomyosarcoma of bone: a clinicopathologic and immunohistochemical study of 142 cases.

Pathologica·2025
Same author

Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review.

Anti-cancer drugs·2025
Same journal

Increased 18F-FDG Avidity on PET/CT During Treatment for Rhabdomyosarcoma Confirmed to Be Mature Rhabdomyoblasts.

Journal of pediatric hematology/oncology·2026
Same journal

Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors.

Journal of pediatric hematology/oncology·2026
Same journal

Frequent Use of Hematologic Testing in Children Admitted for Nonaccidental Trauma.

Journal of pediatric hematology/oncology·2026
Same journal

Unresponsive Systemic Mastocytosis in a Young AML With RUNX1::RUNX1T1 Fusion With Rare KIT c.1255_1257delGAC Mutation: A Clinical Deadlock.

Journal of pediatric hematology/oncology·2026
Same journal

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same journal

Diagnostic Pitfalls in Pediatric Acute Promyelocytic Leukemia: All-trans Retinoic Acid-Associated Hypercalcemia Mimicking Fungal Meningitis and the Risks of Azole Coadministration.

Journal of pediatric hematology/oncology·2026
See all related articles

Identifying late relapse in osteosarcoma is challenging. This study found no specific clinical factors predict late relapse, emphasizing the need for prolonged patient follow-up after initial treatment.

Area of Science:

  • Oncology
  • Orthopedic Surgery
  • Cancer Research

Background:

  • Osteosarcoma is a rare bone cancer primarily affecting children and young adults.
  • Late relapse, defined as recurrence more than 4 years after initial treatment, can occur in nonmetastatic osteosarcoma patients.
  • Understanding predictive factors for late relapse is crucial for optimizing patient management and long-term outcomes.

Purpose of the Study:

  • To identify clinical predictive factors for late relapse in patients with nonmetastatic osteosarcoma.
  • To compare clinical features between patients experiencing late (>4 years) versus early relapse.
  • To evaluate the impact of surgical complete remission on survival after relapse.

Main Methods:

  • Retrospective analysis of 648 nonmetastatic osteosarcoma patients treated between 1983 and 1997.

Related Experiment Videos

  • Comparison of clinical characteristics (sex, tumor site/size, histology, biomarkers, surgery type, histologic response) between patients with late and early relapse.
  • Survival analysis to assess postrelapse survival rates based on remission status.

    • Main Results:

    • Late relapse occurred in 3.7% of patients (24 out of 648).
    • Surgical complete remission was achieved in 79% of patients with late relapse.
    • Patients achieving complete remission had significantly better 5-year postrelapse survival (65%) compared to those with early relapse (20%).
    • No significant differences in clinical features were found between late and early relapse groups.

    Conclusions:

    • No specific clinical factors were identified as predictive of late relapse in nonmetastatic osteosarcoma.
    • Achieving surgical complete remission is associated with improved survival after relapse.
    • A prolonged follow-up strategy is recommended for all osteosarcoma patients to monitor for potential late recurrences.